The MCs can be functionalized with high-molecular-weight compounds, including capture molecules for the specific recognition of target tumor cells (e.g., monoclonal anti-HER2, anti-EGFR antibodies, bispecific anti-EGFR antibodies [4,10,29]), short interfering RNA recognizing programmed cell death protein 1 mRNA [30], and low-molecular-weight antitumor agents (e.g., gemcitabine, 5-fluorouracil, phthalocyanines, and doxorubicin [6,15,31,32]). The gene discussed is EGFR; the disease is neoplasm.